ClinicalTrials.gg
CompletedNCT01142466REMAINUpdated Feb 27, 2014Results posted

A Phase IV Study of Rebif ® 44mcg Administered Three Times Per Week by Subcutaneous Injection Compared With no Treatment in the Therapy of Relapsing Multiple Sclerosis After Mitoxantrone

A Phase 4 interventional study of Interferon beta-1a (Rebif) in Multiple Sclerosis, Relapsing-Remitting, sponsored by Merck KGaA, Darmstadt, Germany. Completed. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2014-02-27.

Sponsored by Merck KGaA, Darmstadt, Germany · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies testing Interferon beta-1a in Multiple Sclerosis, Relapsing-Remitting — none open to participants now, none under way, none of them phase 3. Interferon beta-1a · Multiple Sclerosis, Relapsing-Remitting.

Enrollment
14th of 21
30 · median 80
Started
2005
with 3 others
Phase 4
13 of 21
none open now
Registered
14th of 21
by date
Lead sponsor
5 of 21
Merck KGaA, Darmstadt, Germany

Among the 21 studies testing Interferon beta-1a in Multiple Sclerosis, Relapsing-Remitting, this one is the 14th largest by enrollment, is one of 4 that started in 2005, is one of 13 in phase 4, and was the 14th registered.

Multiple Sclerosis, Relapsing-Remitting

618 studies on the registry are indexed under Multiple Sclerosis, Relapsing-Remitting; 83 are open to participants now.

Browse Multiple Sclerosis, Relapsing-Remitting studies →

Open to participants now

None of the 21 studies testing Interferon beta-1a in Multiple Sclerosis, Relapsing-Remitting is open now. The open studies under Multiple Sclerosis, Relapsing-Remitting, anywhere →

About Interferon beta-1a

Interferon beta-1a: first FDA approval 1996 (AVONEX), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 61 Multiple Sclerosis, Relapsing-Remitting studies recruiting now, 11 (18%) set no upper age limit and 44 (72%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 21 studies testing Interferon beta-1a in Multiple Sclerosis, Relapsing-Remitting as a file.
02

Study summary

In the course of therapy escalation, the multiple sclerosis (MS) subjects with high activity of disease receive mainly mitoxantrone. The duration of therapy is limited because of a cumulative dose for life (140 mg/m\^2 body surface area). In practice lower doses of mitoxantrone (60-120 mg/m\^2 body surface area) are being used. The specific reason for this limited total dose are potential cardiotoxic side effects of mitoxantrone. Once this cumulative dose of mitoxantrone is reached and the subject becomes stable, there is the question for subsequent therapy. A possibility at this time, is the so-called "de-escalation", therefore reducing the subject back to immunomodulating basic treatment.

The target of this open-label, randomised, multicentric, comparative, parallel-group study was to inquire systematically into the use and course of basic therapy with Rebif 44 mcg thrice weekly (tiw) for a larger number of subjects.

Read the detailed description

Multiple sclerosis is a chronic, inflammatory, demyelinating disease of the central nervous system (CNS) and is one of the most common causes of neurological disability in young adults. It is characterised by multi-focal recurrent attacks of neurological symptoms and signs with variable recovery. Eventually, the majority of subjects develop a progressive clinical course. The exact cause of MS is unknown, although an autoimmune process has been implicated. Genetic susceptibility plays a role in disease initiation but unidentified environmental factors may also be involved. Three clinical forms of MS are recognized: primary progressive multiple sclerosis (PPMS), secondary progressive multiple sclerosis (SPMS) and relapsing remitting multiple sclerosis (RRMS). Primary progressive subjects are characterised by slow and steady accumulation of neurological deficits from onset without superimposed attacks. Subjects with RRMS have exacerbations or relapses with subsequent variable recovery (remission). Secondary progressive multiple sclerosis is characterised by the steady accumulation of significant and persistent neurological deficit with or without superimposed relapses.

Rebif [recombinant interferon (IFN) beta-1a] has been tested in a series of studies in MS subjects at doses ranging from 22 mcg to 132 mcg weekly with a dose frequency ranging from weekly (qw) to tiw. Rebif has been found to be well tolerated in all clinical pharmacology studies, even at high doses (up to 66 mcg/m\^2). In later phase trials, Rebif has been tested across a broad range of doses, for varying duration, and in different stages of MS disease. Dose testing has ranged from 22 mcg to 132 mcg weekly with frequency of administration being qw to tiw.

OBJECTIVES

Primary objective:

  • To asses if treatment with Rebif 44 mcg tiw compared with subjects not treated during 96 weeks can maintain or prolong clinical or magnetic resonance imaging (MRI) stability after previous treatment with mitoxantrone

Secondary objectives:

  • To compare the mean number of T2 active lesions, defined as new or enlarging T2 lesions, per subject per scan during 96 weeks of treatment with Rebif 44 mcg three times per week with subjects not treated
  • To assess the safety and efficacy of Rebif 44 mcg

This was an open-label, randomised, multicentric, comparative, parallel-group study with a neurologist blinded to treatment for performing neurologic exams and a neuro-radiologist blinded to treatment for assessing central MRI scans. The study was divided into a screening phase (up to 28 days before the start of IFN-beta-1a treatment), a treatment phase of 96 weeks as well as a follow-up period of 4 weeks for subjects with ongoing serious adverse events (SAEs) at week 96. The study consisted of 2 groups to compare the therapeutic effect of high dose, high frequency IFN beta-1a therapy (Rebif 44 mcg) to subjects who will not be treated with Rebif 44 mcg. Subjects of both groups were previously treated with mitoxantrone in the \< 3 months prior to study inclusion. Subjects assigned to no treatment were switched to Rebif 44 mcg x 3 after reaching the primary endpoint or defined stopping criteria. The treatment period of this study begun with the completion of all baseline evaluations and the initiation of study drug treatment on Study Day 1 (baseline visit) and continues through until completion of the treatment period at the Week 96 visit.

03

Conditions studied

  • Multiple Sclerosis, Relapsing-Remitting

Keywords

  • Multiple sclerosis
  • Expanded Disability Status Scale
  • Multiple Sclerosis, Relapsing-Remitting
  • Rebif
  • Beta-1, interferon
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject who had given written .
  • Subjects with definite RRMS or SPMS with relapses
  • Subjects with EDSS 1-6
  • Subjects aged between 18-60 years
  • Subjects who were escalated to mitoxantrone due to high relapse activity or MRI activity (not due to EDSS progression exclusively)
  • Subjects who may not have a confirmed 1 point EDSS progression (0.5 points for EDSS >5.5) within the last 9 months
  • Subjects free of relapses over the last 6 months
  • Subjects with last mitoxantrone treatment between 1 and 6 months prior to screening
  • Subjects treated with mitoxantrone for minimum 9 months and maximum 36 months, total cumulative dose being 40-120 mg/m\^2
  • Female subjects who must be neither pregnant nor breast-feeding and must lack , as defined by either:

    1. Being or surgically sterile,or
    2. Using a hormonal , intra-uterine device, diaphragm with spermicide or condom with spermicide for the duration of the study. Confirmation that the subject is not pregnant must be established by a negative serum or urinary human chorionic gonadotropin (hCG) test within 7 days prior to start of study treatment. A pregnancy test is not required if the subject is post menopausal or surgically sterile.

Exclusion criteria

Exclusion Criteria:

  • Subject who has received any cytokine or anti-cytokine therapy within the 3 months prior to study Day 1
  • Subject who has been escalated to mitoxantrone due to EDSS progression
  • Subject with an ongoing MS relapse
  • Subject with PPMS
  • Subject with SPMS without superimposed relapses
  • Subject who has received immunomodulatory treatment other than IFN-beta or glatiramer acetate before mitoxantrone
  • Subject who has previously received total lymphoid irradiation
  • Subject who has received oral or systemic or adrenocorticotrophic hormone ACTH within 30 days of study Day 1
  • Subject who has received intravenous immunoglobulins or underwent plasmapheresis within the 6 months prior to study day 1
  • Subject who has received immunomodulatory or therapy (including but not limited to cyclophosphamide, cyclosporin, methotrexate, azathioprine, linomide, teriflunomide, natalizumab, laquinimod, Campath) within the 12 months prior to study Day 1
  • Subject who requires chronic or monthly pulse corticosteroids during the study
  • Subject who has received any drug or experimental procedure within 12 month of study Day 1
  • Subject who has inadequate liver function, defined by a total , (AST) or alanine aminotransferase (ALT) or alkaline phosphatase greater than 2.5 times the values.
  • Subject who has inadequate bone marrow reserve, defined as a white blood cell count less than 0.5 times the lower limit of normal
  • Subject who suffers from current disease
  • Subject with known allergy to IFN or the (s)
  • Subject who suffers from major medical or psychiatric illness that in the opinion of the investigator creates undue risk to the subject or could affect compliance with the study protocol
  • Subject treated with drugs other than IFN-beta or glatiramer acetate within 2 years before mitoxantrone
  • Subject with known cardiac or other systemic diseases
  • Subjects who are pregnant.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Rebif (3x44 mcg) Group

    Drug: Interferon beta-1a (Rebif)

  • No intervention
    No treatment Group

Interventions

  • The dosage of IFN-beta-1a , following initial dose titration, was 44 mcg injected subcutaneously (s.c.) tiw. An auto-injector device, Rebiject, was available as an optional aid for the administration of IFN-beta-1a . IFN-beta-1a was administered, if possible, at the same time (preferably in the late afternoon or evening) on the same three days at least 48 hours apart each week.

    Also known as: Rebif

06

What researchers measure

Primary outcomes

  1. Time From Baseline to First Multiple Sclerosis Relapse (in Weeks)

    A qualifying relapse was defined as a new or worsening neurological symptom, in the absence of fever, lasting for \>= 48 hours, and accompanied by an objective change in the relevant (i.e. symptomatic) Kurtzke Functional Systems (KFS).

    Time frame: Baseline through Week 96

Secondary outcomes

  1. Number of Relapse-free Participants

    A qualifying relapse was defined as a new or worsening neurological symptom, in the absence of fever, lasting for \>= 48 hours, and accompanied by an objective change in the relevant (i.e. symptomatic) Kurtzke Functional Systems (KFS).

    Time frame: Baseline through Week 96

  2. Absolute Changes in the Number of T1 Lesions From Baseline to Week 24, 48, 72 and 96

    Analysis of T1 lesions was done using magnetic resonance imaging (MRI) scans.

    Time frame: Baseline to Week 24, 48, 72, and 96

  3. Absolute Changes in the Number of T1-Gadolinium (T1-Gd) Lesions From Baseline to Week 24, 48, 72 and 96

    Analysis of T1-Gadolinium enhancing lesions was done using magnetic resonance imaging (MRI) scans.

    Time frame: Baseline to Week 24, 48, 72, and 96

  4. Absolute Changes in the Number of T2 Lesions From Baseline to Week 24, 48, 72 and 96

    Analysis of T2 lesions was done using magnetic resonance imaging (MRI) scans.

    Time frame: Baseline to Week 24, 48, 72, and 96

  5. Mean Changes in Expanded Disability Status Scale (EDSS) Score From Baseline to Week 12, 24, 36, 48, 60, 72, 84, and 96

    EDSS assesses disability in 8 functional systems. An overall score ranging from 0 (normal) to 10 (death due to MS) was calculated. EDSS progression was defined as increase by at least 1 point if last value of EDSS was equal to 5.5, and by at least 0.5 points if last EDSS was more than 5.5.

    Time frame: Baseline to Week 12, 24, 36, 48, 60, 72, 84, and 96

  6. Number of Participants With Adverse Events (AE) and Serious Adverse Events (SAE)

    AE: any new untoward medical occurrence/worsening of pre-existing medical condition, whether or not related to study drug. SAE: any AE that resulted in death; was life threatening; resulted in persistent/significant disability/incapacity; resulted in/prolonged an existing in-patient hospitalization; was a congenital anomaly/birth defect; or was a medically important condition.

    Time frame: Baseline to Week 96

07

Results

Posted Jun 10, 2011

Participant flow

Participants were enrolled at multiple centres in Germany.

Participant flow — Overall Study
MilestoneRebif 44 McgNo Treatment
Started1515
Completed1213
Not completed32
Withdrew: Adverse event21
Withdrew: Withdrawal by subject11

Outcome measures

PrimaryTime From Baseline to First Multiple Sclerosis Relapse (in Weeks)

A qualifying relapse was defined as a new or worsening neurological symptom, in the absence of fever, lasting for \>= 48 hours, and accompanied by an objective change in the relevant (i.e. symptomatic) Kurtzke Functional Systems (KFS).

Time frame:
Baseline through Week 96
Reported as:
Mean · weeks
Time From Baseline to First Multiple Sclerosis Relapse (in Weeks)
weeksRebif 44 McgNo Treatment
Time From Baseline to First Multiple Sclerosis Relapse (in Weeks)35.5 ± 40.840.9 ± 28.7
Statistical analysis
  • Rebif 44 Mcg vs No Treatment · Log Rank · p = 0.1384
SecondaryNumber of Relapse-free Participants

A qualifying relapse was defined as a new or worsening neurological symptom, in the absence of fever, lasting for \>= 48 hours, and accompanied by an objective change in the relevant (i.e. symptomatic) Kurtzke Functional Systems (KFS).

Time frame:
Baseline through Week 96
Reported as:
Number · participants
Number of Relapse-free Participants
participantsRebif 44 McgNo Treatment
Number of Relapse-free Participants107
Statistical analysis
  • Rebif 44 Mcg vs No Treatment · Fisher Exact · p = 0.2635
SecondaryAbsolute Changes in the Number of T1 Lesions From Baseline to Week 24, 48, 72 and 96

Analysis of T1 lesions was done using magnetic resonance imaging (MRI) scans.

Time frame:
Baseline to Week 24, 48, 72, and 96
Reported as:
Mean · T1 lesions
Absolute Changes in the Number of T1 Lesions From Baseline to Week 24, 48, 72 and 96
T1 lesionsRebif 44 McgNo Treatment
Week 24 (n= 13,15)-0.5 ± 4.4-0.9 ± 8.9
Week 48 (n= 13,13)-0.8 ± 4.31.5 ± 11.2
Week 72 (n= 12,12)-0.8 ± 9.2-3.6 ± 12.0
Week 96 (n= 12,12)-1.8 ± 5.5-2.3 ± 11.6
SecondaryAbsolute Changes in the Number of T1-Gadolinium (T1-Gd) Lesions From Baseline to Week 24, 48, 72 and 96

Analysis of T1-Gadolinium enhancing lesions was done using magnetic resonance imaging (MRI) scans.

Time frame:
Baseline to Week 24, 48, 72, and 96

No measurements were reported for this outcome.

SecondaryAbsolute Changes in the Number of T2 Lesions From Baseline to Week 24, 48, 72 and 96

Analysis of T2 lesions was done using magnetic resonance imaging (MRI) scans.

Time frame:
Baseline to Week 24, 48, 72, and 96
Reported as:
Mean · T2 lesions
Absolute Changes in the Number of T2 Lesions From Baseline to Week 24, 48, 72 and 96
T2 lesionsRebif 44 McgNo Treatment
Week 24 (n= 13,15)-1.2 ± 4.01.0 ± 6.0
Week 48 (n= 13,13)0.2 ± 8.53.2 ± 10.1
Week 72 (n= 12,13)-1.8 ± 3.33.1 ± 14.1
Week 96 (n= 12,12)-3.1 ± 7.62.1 ± 15.4
SecondaryMean Changes in Expanded Disability Status Scale (EDSS) Score From Baseline to Week 12, 24, 36, 48, 60, 72, 84, and 96

EDSS assesses disability in 8 functional systems. An overall score ranging from 0 (normal) to 10 (death due to MS) was calculated. EDSS progression was defined as increase by at least 1 point if last value of EDSS was equal to 5.5, and by at least 0.5 points if last EDSS was more than 5.5.

Time frame:
Baseline to Week 12, 24, 36, 48, 60, 72, 84, and 96
Reported as:
Mean · Units on a Scale
Mean Changes in Expanded Disability Status Scale (EDSS) Score From Baseline to Week 12, 24, 36, 48, 60, 72, 84, and 96
Units on a ScaleRebif 44 McgNo Treatment
Week 12 (n= 14, 15)-0.1 ± 0.5-0.1 ± 0.4
Week 24 (n= 14, 15)0.3 ± 0.60.1 ± 0.4
Week 36 (n= 13, 14)0.5 ± 0.8-0.2 ± 0.4
Week 48 (n= 14, 14)0.5 ± 0.80.2 ± 0.7
Week 60 (n= 10, 11)0.4 ± 0.80.0 ± 1.0
Week 72 (n= 12, 13)0.3 ± 0.60.2 ± 0.9
Week 84 (n= 12, 13)0.5 ± 0.90.2 ± 0.9
Week 96 (n= 12, 13)0.1 ± 0.80.3 ± 1.0
SecondaryNumber of Participants With Adverse Events (AE) and Serious Adverse Events (SAE)

AE: any new untoward medical occurrence/worsening of pre-existing medical condition, whether or not related to study drug. SAE: any AE that resulted in death; was life threatening; resulted in persistent/significant disability/incapacity; resulted in/prolonged an existing in-patient hospitalization; was a congenital anomaly/birth defect; or was a medically important condition.

Time frame:
Baseline to Week 96
Reported as:
Number · participants
Number of Participants With Adverse Events (AE) and Serious Adverse Events (SAE)
participantsRebif 44 McgNo Treatment
Adverse Events1514
Serious Adverse Events51

Adverse events

Collected over Baseline to Week 96 or premature termination or unscheduled visit.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rebif 44 Mcg—5/15 (33.3%)15/15 (100%)
No Treatment—1/15 (6.7%)14/15 (93.3%)
Most frequent serious events
Most frequent serious events
EventRebif 44 McgNo Treatment
ConvulsionNervous system disorders1/150/15
Status EpilepticusNervous system disorders1/150/15
Angle Closure GlaucomaEye disorders1/150/15
Cholecystitis chronicHepatobiliary disorders1/150/15
CholelithiasisHepatobiliary disorders1/150/15
Haemorrhoid OperationGastrointestinal disorders1/150/15
Gastroenteritis salmonellaGastrointestinal disorders1/150/15
DepressionNervous system disorders0/151/15
Most frequent other events
Showing 10 of 27
Most frequent other events
EventRebif 44 McgNo Treatment
NasopharyngitisInfections and infestations6/154/15
HeadacheNervous system disorders4/152/15
Influenza like illnessGeneral disorders3/152/15
DiarrhoeaGastrointestinal disorders0/153/15
InfectionInfections and infestations3/150/15
RhinitisInfections and infestations3/150/15
Urinary tract infectionRenal and urinary disorders2/152/15
ArthralgiaMusculoskeletal and connective tissue disorders2/151/15
Back PainMusculoskeletal and connective tissue disorders2/151/15
CoughRespiratory, thoracic and mediastinal disorders2/151/15

Baseline characteristics

Age, Continuous
Age, Continuous(years)Rebif 44 McgNo TreatmentTotal
Mean43.8 ± 7.044.3 ± 6.544.1 ± 6.6
Sex: Female, Male
Sex: Female, Male(Participants)Rebif 44 McgNo TreatmentTotal
Female11920
Male369
Expanded Disability Status Scale (EDSS)
Expanded Disability Status Scale (EDSS)(Units on Scale)Rebif 44 McgNo TreatmentTotal
Mean4.1 ± 1.44.3 ± 1.04.2 ± 1.2
08

Study locations

No study locations are listed for this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2005, a primary completion of Dec 2009 and a completion of Jan 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2011, 1 year 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 10, 2010
First posted
Jun 11, 2010
Start
Dec 2005
Primary completionActual
Dec 2009
CompletionActual
Jan 2010
Results first posted
Jun 10, 2011
Last update
Feb 27, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 27, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01142466
Collaborators
Gesellschaft für Therapieforschung mbH
Responsible party
Sponsor
First posted
Jun 11, 2010
Start date
Dec 2005
Primary completion
Dec 2009
Completion
Jan 2010
Results posted
Jun 10, 2011
Last update
Feb 27, 2014

Study contacts

Sigbert Jahn, PD Dr. med
study director · Merck Serono GmbH, Germany

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Interferon beta-1a

Start the discussion